Innovent Biologics, Inc. (HKG: 1801)

Hong Kong · Delayed Price · Currency is HKD

48.85

+1.45 (3.06%)

Oct 10, 2024, 4:08 PM HKT

Innovent Biologics Employees

Innovent Biologics had 4,872 employees as of December 31, 2023. The number of employees decreased by 422 or -7.97% compared to the previous year.

Employees

4,872

Change (1Y)

-422

Growth (1Y)

-7.97%

Revenue / Employee

1.52M HKD

Profits / Employee

-261.61K HKD

Market Cap

79.68B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	4,872	-422	-7.97%
Dec 31, 2022	5,294	-274	-4.92%
Dec 31, 2021	5,568	2,289	69.81%
Dec 31, 2020	3,279	1,297	65.44%
Dec 31, 2019	1,982	1,023	106.67%
Dec 31, 2018	Pro	Pro	Pro

Innovent Biologics News

4 days ago - Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
15 days ago - Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis - PRNewsWire
24 days ago - Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress - PRNewsWire
24 days ago - Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress - PRNewsWire
4 weeks ago - Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 - PRNewsWire
4 weeks ago - Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC - PRNewsWire
4 weeks ago - Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation - PRNewsWire
5 weeks ago - Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma - PRNewsWire